Acarix Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acarix (STO:ACARIX) Full Year 2024 Results

Key Financial Results

• Revenue: kr6.20m (flat on FY 2023).
• Net loss: kr66.2m (loss narrowed by 15% from FY 2023).
• kr0.072 loss per share (improved from kr0.16 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Acarix EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 30%.

The primary driver behind last 12 months revenue was the USA segment contributing a total revenue of kr3.62m (58% of total revenue). The largest operating expense was General & Administrative costs, amounting to kr46.6m (65% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of kr186.0k. Explore how ACARIX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 5.4% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 4 warning signs for Acarix (2 are significant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.